Setidegrasib + Chemotherapy for Pancreatic Cancer

This trial aims to determine if adding a new drug, setidegrasib, to standard chemotherapy (mFOLFIRINOX or NALIRIFOX) can extend the lives of people with pancreatic cancer. It targets individuals whose cancer has spread (metastatic) and who have the KRAS G12D mutation. Participants will receive either setidegrasib with chemotherapy or a placebo with chemotherapy, and researchers will compare the outcomes. This trial suits those with metastatic pancreatic cancer with the KRAS G12D mutation who cannot undergo surgery or radiation for a cure. As a Phase 3 trial, it represents the final step before potential FDA approval, offering participants a chance to contribute to a treatment that could soon become widely available.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss your specific medications with the study doctor to understand any potential interactions or requirements.

Studies have shown that setidegrasib is generally well-tolerated by patients. Most side effects have been mild and temporary, such as reactions to the infusion. In earlier research, only a few patients stopped treatment due to side effects. Additionally, in studies with patients who have advanced pancreatic cancer, setidegrasib showed promising results without causing serious side effects. This suggests that setidegrasib may be a safe option for people with the KRAS G12D mutation in pancreatic cancer. However, more studies are needed to confirm its safety when used with standard chemotherapy treatments like mFOLFIRINOX or NALIRIFOX.¹²³⁴⁵

Setidegrasib is unique because it introduces a new active ingredient to the treatment of pancreatic cancer, potentially offering an additional mechanism of action beyond standard chemotherapy. Most treatments for pancreatic cancer, like mFOLFIRINOX and NALIRIFOX, focus solely on traditional chemotherapy components. However, Setidegrasib works differently by possibly targeting pathways that standard treatments do not address, which could enhance their effectiveness. Researchers are excited about this because it may improve outcomes for patients who respond inadequately to current options.

Research has shown that setidegrasib may help treat pancreatic cancer, particularly in patients with the KRAS G12D genetic mutation. In earlier studies, about 24% of patients with this cancer type experienced tumor shrinkage. On average, these patients lived for 10.3 months, a notable outcome given the aggressive nature of pancreatic cancer. Setidegrasib also demonstrated a high success rate in disease control, with 84.4% of patients experiencing stable disease or better. In this trial, participants will receive either setidegrasib or a placebo, each combined with chemotherapy, to evaluate whether setidegrasib can improve outcomes for those facing this challenging cancer.²³⁴⁶⁷